Thrombin generation assay as a biomarker of cardiovascular outcomes and mortality: A narrative review

Letícia Gonçalves Resende Ferreira1, Roberta Carvalho Figueiredo1, Maria das Graças Carvalho2

  • 1Campus Centro Oeste - Universidade Federal de São João del-Rei, Divinópolis, Brazil.

Thrombosis Research
|November 5, 2022
PubMed

Insights

Thrombin generation assay (TGA) shows potential for cardiovascular risk assessment. Further research is needed to clarify its association with cardiovascular events and mortality.

Area of Science:

  • Biochemistry
  • Cardiology
  • Hematology

Background:

  • Cardiovascular diseases (CVDs) are the leading global cause of death.
  • Inflammation and hemostasis interact significantly in CVD pathophysiology.
  • Thrombin, a key clotting enzyme, is investigated as a potential cardiovascular risk biomarker.

Purpose of the Study:

  • To review and summarize studies evaluating thrombin generation assay (TGA) parameters in relation to cardiovascular events.
  • To explore the association between TGA and cardiovascular/all-cause mortality.
  • To investigate the role of TGA in understanding CVD pathophysiology and prevention.

Main Methods:

  • Utilized the Calibrated Automated Thrombogram (CAT) method for thrombin generation assay (TGA).
  • Reviewed numerous prospective studies investigating hemostatic system function.
  • Analyzed TGA parameters in relation to arterial thrombosis, acute myocardial infarction (AMI), stroke, and mortality.

Main Results:

  • TGA is a laboratory tool for globally evaluating hemostatic system function.
  • The association of TGA with arterial thrombosis is a recent area of interest.
  • The link between thrombin generation and cardiovascular events/mortality is inconsistently reported and requires further investigation.

Conclusions:

  • Thrombin generation analysis is a promising tool for estimating thrombotic disease risk.
  • Understanding TGA's relationship with CVDs can enhance knowledge of coronary and cerebrovascular disease processes.
  • TGA may offer novel approaches to cardiovascular disease prevention.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...